Shots:
- The US FDA has received a De Novo 510(k) application for the Breast Cancer Locator (BCL) System to improve the accuracy of breast-conserving surgery (lumpectomy)
- Cairn Surgical completed its US pivotal trial of the system, with data to be presented at the ASBrS’26 & incl. in the FDA filing, along with earlier data, published in The ASO, showing the system enabled successful breast tumor removal with negative margins in 94% pts
- The BCL System enhances lumpectomy by using supine MRI data to create a patient-specific 3D-printed guide that reflects tumor shape, size, & location, helping surgeons accurately excise tumors, achieve clear margins, & improve surgical workflow
Ref:Â Businesswire |Â Image:Â Cairn Surgical | Press Release
Related News: QIAGEN Wins the US FDA Clearance for QIAstat-Dx GI Panels on QIAstat-Dx Rise Syndromic Testing System
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
